Related Research
Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. Int J Cancer. 2018;142:414–23.
Zeitoun JD, Baron G, Vivot A, Atal I, Downing NS, Ross JS, et al.
Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56:1–7.
Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al.
Approvals in 2016: questioning the clinical benefit of anticancer therapies. Nat Rev Clin Oncol. 2017;14:135–6.
Booth CM, Del Paggio JC.
Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE continuous innovation indicators (CII). Drugs Context. 2017;6:212507.
Brooks N, Campone M, Paddock S, Shortenhaus S, Grainger D, Zummo J, et al.
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530.
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A.
Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Eur J Cancer. 2017;82:66–71.
Grossmann N, Del Paggio JC, Wolf S, Sullivan R, Booth CM, Rosian K, et al.
Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA. 2017;318:626–36.
Naci H, Smalley KR, Kesselheim AS.
Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. Milbank Q. 2017;95:261–90.
Naci H, Wouters OJ, Gupta R, Ioannidis JPA.
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ. 2017;357:j1680.
Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS.
Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382–90.
Salas-Vega S, Iliopoulos O, Mossialos E.
Meaningful endpoints for therapies approved for hematologic malignancies. Cancer. 2017;123:1689–94.
Smith BD, DeZern AE, Bastian AW, Durie BGM.
Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration. J Natl Cancer Inst. 2018;110:486–92.
Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, et al.
Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? ESMO Open. 2016;1:e000125.
Grossmann N, Wild C.
Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clin Pharmacol Ther. 2015;98:534–41.
Hoekman J, Boon WP, Bouvy JC, Ebbers HC, de Jong JP, De Bruin ML.
Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175:1992–4.
Kim C, Prasad V
Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. BMJ. 2015;351:h4679.
Wang B, Kesselheim AS.
Review and comparison of clinical evidence submitted to support European medicines agency market authorization of orphan-designated oncological treatments. Orphanet J Rare Dis. 2015;10:139.
Winstone J, Chadda S, Ralston S, Sajosi P.
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. 2014;311:368–77.
Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS.
Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–36.
Fojo T, Mailankody S, Lo A.
Approval probabilities and regulatory review patterns for anticancer drugs in the European Union. Crit Rev Oncol Hematol. 2013;87:112–21.
Hartmann M, Mayer-Nicolai C, Pfaff O.
Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. Oncologist. 2013;18:104–11.
Martell RE, Sermer D, Getz K, Kaitin KI.
Preapproval and postapproval availability of published comparative efficacy research on biological agents. Am J Health Syst Pharm. 2013;70:1250–5.
Thomas RH, Freeman MK, Hughes PJ.
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.
Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305:1786–9.
Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ.
Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103:636–44.
Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R.
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305:2320–6.
Kesselheim AS, Myers JA, Avorn J.
When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.
Ocana A, Tannock IF.
Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010;102:230–43.
Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R.
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized trial. J Clin Oncol. 2009;27:6243–50.
Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R.
